Alanine transaminase(Redirected from Alanine aminotransferase)
Alanine transaminase (ALT) is a transaminase enzyme (EC 22.214.171.124). It is also called alanine aminotransferase (ALAT) and was formerly called serum glutamate-pyruvate transaminase (SGPT) or serum glutamic-pyruvic transaminase (SGPT) and was first characterized in the mid-1950s by Arthur Karmen and colleagues. ALT is found in plasma and in various body tissues, but is most common in the liver. It catalyzes the two parts of the alanine cycle. Serum ALT level, serum AST (aspartate transaminase) level, and their ratio (AST/ALT ratio) are commonly measured clinically as biomarkers for liver health. The tests are part of blood panels.
|Locus||Chr. 8 q24.2-qter|
|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / EGO|
ALT (and all aminotransferases) require the coenzyme pyridoxal phosphate, which is converted into pyridoxamine in the first phase of the reaction, when an amino acid is converted into a keto acid.
ALT is commonly measured clinically as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. When used in diagnostics, it is almost always measured in international units/liter (IU/L). While sources vary on specific reference range values for patients, 10-40 IU/L is the standard reference range for experimental studies. Alanine transaminase shows a marked diurnal variation.
The ratio of ALT to AST (aspartate aminotransferase) also has clinical significance.
Test results should always be interpreted using the reference range from the laboratory that produced the result. However typical reference intervals for ALT are:
|Patient type||Reference ranges|
|Female||≤ 34 IU/L|
|Male||≤ 52 IU/L|
Significantly elevated levels of ALT (SGPT) often suggest the existence of other medical problems such as viral hepatitis, diabetes, congestive heart failure, liver damage, bile duct problems, infectious mononucleosis, or myopathy, so ALT is commonly used as a way of screening for liver problems. Elevated ALT may also be caused by dietary choline deficiency. However, elevated levels of ALT do not automatically mean that medical problems exist. Fluctuation of ALT levels is normal over the course of the day, and they can also increase in response to strenuous physical exercise.
When elevated ALT levels are found in the blood, the possible underlying causes can be further narrowed down by measuring other enzymes. For example, elevated ALT levels due to hepatocyte damage can be distinguished from bile duct problems by measuring alkaline phosphatase. Also, myopathy-related elevations in ALT should be suspected when the aspartate transaminase (AST) is greater than ALT; the possibility of muscle disease causing elevations in liver tests can be further explored by measuring muscle enzymes, including creatine kinase. Many drugs may elevate ALT levels, including Zileuton, omega-3-acid ethyl esters (Lovaza), anti-inflammatory drugs, antibiotics, cholesterol medications, some antipsychotics such as risperidone, and anticonvulsants.. Paracetamol (also known as acetaminophen) may also elevate ALT levels.
For years, the American Red Cross used ALT testing as part of the battery of tests to ensure the safety of its blood supply by deferring donors with elevated ALT levels. The intent was to identify donors potentially infected with hepatitis C because no specific test for that disease was available at the time. Prior to July 1992, widespread blood donation testing in the USA for hepatitis C was not carried out by major blood banks. With the introduction of second-generation ELISA antibody tests for hepatitis C, the Red Cross changed the ALT policy. As of July 2003[update], donors previously disqualified for elevated ALT levels and no other reason may be reinstated as donors by contacting the donor-counseling department of their regional Red Cross organization.
In 2000, the American Association for Clinical Chemistry determined that the appropriate terminology for AST and ALT are aspartate aminotransferase and alanine aminotransferase. The term transaminase is outdated and no longer used in liver disease.
- Karmen A, Wroblewski F, Ladue JS (Jan 1955). "Transaminase activity in human blood". The Journal of Clinical Investigation. 34 (1): 126–31. PMC . PMID 13221663. doi:10.1172/JCI103055.
- Wang CS, Chang TT, Yao WJ, Wang ST, Chou P (April 2012). "Impact of increasing alanine aminotransferase levels within normal range on incident diabetes". Journal of the Formosan Medical Association = Taiwan Yi Zhi. 111 (4): 201–8. PMID 22526208. doi:10.1016/j.jfma.2011.04.004.
- Ghouri N, Preiss D, Sattar N (September 2010). "Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data". Hepatology. 52 (3): 1156–61. PMID 20658466. doi:10.1002/hep.23789.
- "Alanine aminotransferase: analyte monograph" (PDF). Association for Clinical Biochemistry and Laboratory Medicine. Retrieved 7 October 2013.
- Paul T. Giboney M.D., Mildly Elevated Liver Transaminase Levels in the Asymptomatic Patient, American Family Physician.
- Koski RR (2008). "Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia". Pharmacy and Therapeutics. 33 (5): 271–303. PMC .
- Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC (July 2006). "Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial". JAMA. 296 (1): 87–93. PMID 16820551. doi:10.1001/jama.296.1.87.
- Red Cross Donor Requirements
- Clin Chem 2000;46:2027-2049
- Alanine transaminase at the US National Library of Medicine Medical Subject Headings (MeSH)
- ALT: analyte monograph; The Association for Clinical Biochemistry and Laboratory Medicine
- Alanine aminotransferase (ALT) at Lab Tests Online